Search

We describe a female patient suffering from severe chronic non-bacterial osteomyelitis (CNO) with systemic inflammation and advanced malnutrition and complete deficiency of myeloperoxidase (MPO). CNO is a rare autoinflammatory bone disorder associated with dysregulation of the innate immune system. MPO deficiency is a genetic disorder with partial or complete absence of the phagocyte peroxidase MPO. MPO deficiency has no established clinical phenotype but reports indicate increased susceptibility to infection and chronic inflammation. The patients symptoms began at 10 years of age with pain in the thighs, systemic inflammation and malnutrition. She was diagnosed with CNO at 14 years of age. Treatment with nonsteroidal anti-inflammatory drugs, corticosteroids, bisphosphonates or IL1-receptor antagonists (anakinra) did not relieve the symptoms. However, the patient responded instantly and recovered from her clinical symptoms when treated with TNF alpha blockade (adalimumab). Three years after treatment initiation adalimumab was withdrawn, resulting in rapid symptom recurrence. When reintroducing adalimumab, the patient promptly responded and went into remission. In addition to clinical and laboratory profiles, neutrophil functions (reactive oxygen species, ROS; neutrophil extracellular traps, NETs; degranulation; apoptosis; elastase activity) were investigated both in a highly inflammatory state (without treatment) and in remission (on treatment). At diagnosis, neither IL1 beta, IL6, nor TNF alpha was significantly elevated in serum, but since TNF alpha blockade terminated the inflammatory symptoms, the disease was likely TNF alpha-driven. All neutrophil parameters were normal both during treatment and treatment withdrawal, except for MPO-dependent intracellular ROS- and NET formation. The role of total MPO deficiency for disease etiology and severity is discussed., Funding Agencies|This research received financial support from the Swedish Research Council - Medicine (2018-03077, 2019-01123), the King Gustaf V Memorial Foundation (2015-0165, 2017-0368, 2021-0804, 2022-0873), the Swedish state under the ALF agreement (ALFGBG-726801), t [2018-03077, 2019-01123]; Swedish Research Council - Medicine [2015-0165, 2017-0368, 2021-0804, 2022-0873]; King Gustaf V Memorial Foundation [ALFGBG-726801]; Swedish state under the ALF agreement [2018-2344, 2019-3102]; Wilhelm and Martina Lundgrens Scientific Foundation [2018-02579, 2021-04110]; Magnus Bergwall foundation; Alfred Ahlqvists foundation - Swedish pharmacy Society [VGFOUREG-858661, VGFOUREG-981130]; Ingabritt and Arne Lundberg Foundation

We describe a female patient suffering from severe chronic non-bacterial osteomyelitis (CNO) with systemic inflammation and advanced malnutrition and complete deficiency of myeloperoxidase (MPO). CNO is a rare autoinflammatory bone disorder associated with dysregulation of the innate immune system. MPO deficiency is a genetic disorder with partial or complete absence of the phagocyte peroxidase MPO. MPO deficiency has no established clinical phenotype but reports indicate increased susceptibility to infection and chronic inflammation. The patients symptoms began at 10 years of age with pain in the thighs, systemic inflammation and malnutrition. She was diagnosed with CNO at 14 years of age. Treatment with nonsteroidal anti-inflammatory drugs, corticosteroids, bisphosphonates or IL1-receptor antagonists (anakinra) did not relieve the symptoms. However, the patient responded instantly and recovered from her clinical symptoms when treated with TNF alpha blockade (adalimumab). Three years after treatment initiation adalimumab was withdrawn, resulting in rapid symptom recurrence. When reintroducing adalimumab, the patient promptly responded and went into remission. In addition to clinical and laboratory profiles, neutrophil functions (reactive oxygen species, ROS; neutrophil extracellular traps, NETs; degranulation; apoptosis; elastase activity) were investigated both in a highly inflammatory state (without treatment) and in remission (on treatment). At diagnosis, neither IL1 beta, IL6, nor TNF alpha was significantly elevated in serum, but since TNF alpha blockade terminated the inflammatory symptoms, the disease was likely TNF alpha-driven. All neutrophil parameters were normal both during treatment and treatment withdrawal, except for MPO-dependent intracellular ROS- and NET formation. The role of total MPO deficiency for disease etiology and severity is discussed., Funding Agencies|This research received financial support from the Swedish Research Council - Medicine (2018-03077, 2019-01123), the King Gustaf V Memorial Foundation (2015-0165, 2017-0368, 2021-0804, 2022-0873), the Swedish state under the ALF agreement (ALFGBG-726801), t [2018-03077, 2019-01123]; Swedish Research Council - Medicine [2015-0165, 2017-0368, 2021-0804, 2022-0873]; King Gustaf V Memorial Foundation [ALFGBG-726801]; Swedish state under the ALF agreement [2018-2344, 2019-3102]; Wilhelm and Martina Lundgrens Scientific Foundation [2018-02579, 2021-04110]; Magnus Bergwall foundation; Alfred Ahlqvists foundation - Swedish pharmacy Society [VGFOUREG-858661, VGFOUREG-981130]; Ingabritt and Arne Lundberg Foundation

We describe a female patient suffering from severe chronic non-bacterial osteomyelitis (CNO) with systemic inflammation and advanced malnutrition and complete deficiency of myeloperoxidase (MPO). CNO is a rare autoinflammatory bone disorder associated with dysregulation of the innate immune system. MPO deficiency is a genetic disorder with partial or complete absence of the phagocyte peroxidase MPO. MPO deficiency has no established clinical phenotype but reports indicate increased susceptibility to infection and chronic inflammation. The patients symptoms began at 10 years of age with pain in the thighs, systemic inflammation and malnutrition. She was diagnosed with CNO at 14 years of age. Treatment with nonsteroidal anti-inflammatory drugs, corticosteroids, bisphosphonates or IL1-receptor antagonists (anakinra) did not relieve the symptoms. However, the patient responded instantly and recovered from her clinical symptoms when treated with TNF alpha blockade (adalimumab). Three years after treatment initiation adalimumab was withdrawn, resulting in rapid symptom recurrence. When reintroducing adalimumab, the patient promptly responded and went into remission. In addition to clinical and laboratory profiles, neutrophil functions (reactive oxygen species, ROS; neutrophil extracellular traps, NETs; degranulation; apoptosis; elastase activity) were investigated both in a highly inflammatory state (without treatment) and in remission (on treatment). At diagnosis, neither IL1 beta, IL6, nor TNF alpha was significantly elevated in serum, but since TNF alpha blockade terminated the inflammatory symptoms, the disease was likely TNF alpha-driven. All neutrophil parameters were normal both during treatment and treatment withdrawal, except for MPO-dependent intracellular ROS- and NET formation. The role of total MPO deficiency for disease etiology and severity is discussed., Funding Agencies|This research received financial support from the Swedish Research Council - Medicine (2018-03077, 2019-01123), the King Gustaf V Memorial Foundation (2015-0165, 2017-0368, 2021-0804, 2022-0873), the Swedish state under the ALF agreement (ALFGBG-726801), t [2018-03077, 2019-01123]; Swedish Research Council - Medicine [2015-0165, 2017-0368, 2021-0804, 2022-0873]; King Gustaf V Memorial Foundation [ALFGBG-726801]; Swedish state under the ALF agreement [2018-2344, 2019-3102]; Wilhelm and Martina Lundgrens Scientific Foundation [2018-02579, 2021-04110]; Magnus Bergwall foundation; Alfred Ahlqvists foundation - Swedish pharmacy Society [VGFOUREG-858661, VGFOUREG-981130]; Ingabritt and Arne Lundberg Foundation